HHS slams 'under-tested' mRNA technology as Trump cuts Moderna's vaccine funding

The Trump administration's HHS is terminating over $750 million in awards to Moderna for mRNA-based bird flu vaccine production, citing safety concerns and a lack of oversight during the Biden administration, which initially granted the funds. HHS officials stated that mRNA technology remains under-tested and that they would not repeat the mistakes of the prior administration. Moderna acknowledged the funding termination but highlighted the safety profile and robust immune response observed in its Phase 1/2 study, indicating it will explore alternative paths forward for the program.

Analysis

The Trump administration's Department of Health and Human Services (HHS) is terminating awards totaling over $750 million previously allocated to Moderna (MRNA) for the development and production of its mRNA-based H5N1 bird flu vaccines. This decision reverses significant funding, including a $590 million award from the Biden administration's final week in office and an earlier $176 million. HHS Communications Director Andrew Nixon justified the termination by stating that a review concluded continued investment in Moderna’s H5N1 mRNA vaccine was not "scientifically or ethically justifiable," asserting that mRNA technology remains "under-tested" and that the administration aims to avoid repeating perceived mistakes of the previous administration, which allegedly "concealed legitimate safety concerns from the public." This action aligns with a broader shift in federal vaccine priorities, as exemplified by HHS Secretary Robert F. Kennedy Jr.'s recent announcement to remove COVID-19 vaccines from the federal government's recommended list for children and pregnant women. The decision also follows a Senate Republican report suggesting the Biden administration withheld critical safety data regarding myocarditis risks associated with mRNA COVID-19 vaccines. In response to the funding cancellation, Moderna's CEO Stéphane Bancel acknowledged the development but highlighted the "robust immune response and safety profile observed" in the interim analysis of its Phase 1/2 H5 avian flu vaccine study, affirming the company will "explore alternative paths forward for the program."

Key Decisions for Investors

• Investors should re-evaluate Moderna's (MRNA) revenue projections and development timelines for its H5 avian flu vaccine program following the termination of over $750 million in HHS funding, and closely monitor the company's disclosures regarding alternative financing or strategic partnerships.
• The current administration's explicitly critical stance on mRNA technology, citing safety and oversight concerns, signals potential headwinds for companies heavily reliant on this platform, including increased regulatory scrutiny, shifts in public health policy, and potential impacts on future government contracts.
• Closely monitor further policy announcements and regulatory actions from HHS under Secretary Robert F. Kennedy Jr., as the administration's approach could significantly alter the investment landscape and public perception for mRNA-based therapeutics and vaccines beyond Moderna's bird flu program.